The Food and Drug Administration (FDA) has awarded PTC Therapeutics funding amounted to $ 1.6 million to continue the trial in progress Ataluren, experimental drug to treat Duchenne dystrophy. The Phase IIb clinical trial was conducted on 174 patients in 37 centers in 11 countries worldwide, including USA, Canada, Australia and Israel. For several years, PTC Therapeutics, a note of Parent Project, a project born in Italy in 1996 to defeat the Duchenne muscular dystrophy and Becker - has developed this new type of experimental drug that works by allowing the cell to ignore the stop sign in genome and to pursue the correct coding of the dystrophin gene. The premature stop codon in the dystrophin gene is present in approximately 13% of patients with the disease. Primary endpoint of the international clinical trial is to evaluate the effectiveness of the drug on the ability to walking. Data processing with the final clinical results is scheduled for summer 2010.
0 comments:
Post a Comment